CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED....Certain • November 15th, 2004 • Nestor Inc • Services-prepackaged software • Delaware
EXHIBIT 10.13 EXCLUSIVE LICENSE AGREEMENTCertain • July 16th, 1999 • Scientific Learning Corp • Services-educational services • California
RECITALSCertain • August 3rd, 2001 • Omnicell Inc /Ca/ • Electronic computers • California
SECOND AMENDMENT TO LICENSE AGREEMENT M940121 (UNMARKED)Certain • March 23rd, 2000 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([*]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Certain • June 24th, 2004 • Viacell Inc • Services-commercial physical & biological research • Massachusetts
Exhibit 10.15 UNIVERSITY OF ARIZONA AND TELIK RESEARCH AND LICENSE AGREEMENT This Agreement, is made as of this 8th day of January, 2001 (the "Effective Date") between the Arizona Board of Regents (ABOR) for The University of Arizona (UNIVERSITY) and...Certain • September 20th, 2001 • Telik Inc • Pharmaceutical preparations • Arizona
A G R E E M E N TCertain • May 13th, 2010 • United Maritime Group, LLC • Water transportation • Florida
ContractCertain • September 23rd, 2011 • Enphase Energy, Inc. • Semiconductors & related devices
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDED AND RESTATED DEVELOPMENT AND...Certain • February 29th, 2012 • Xenoport Inc • Pharmaceutical preparations • Delaware
* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
Terms and Conditions for the Manufacture of Products by Ben Venue Laboratories, IncCertain • March 9th, 2004 • Medimmune Inc /De • Biological products, (no disgnostic substances) • Delaware
This signed agreement is required to provide services and manufacture your Product at Ben Venue Laboratories, Inc. This agreement covers all Products & services for the development and manufacture of Products for your company at Ben Venue and remains in place until superceded by a formal supply agreement.
EXHIBIT 10.10 GEOCITIES "PAGES THAT PAY" AFFILIATES PROGRAM MERCHANT AGREEMEENT This Merchant Agreement ("Agreement") is entered as of _______________ 1999 (the "Effective Date") by and between GeoCities, a California corporation, with its principal...Certain • September 20th, 1999 • Greatfood Com Inc • Retail-catalog & mail-order houses • California
AMENDMENT NO. 3 TO AGREEMENTCertain • February 16th, 2022 • Idexx Laboratories Inc /De • In vitro & in vivo diagnostic substances
AMENDMENT, effective as of December 28, 2011 (this “Amendment”) to the Agreement, dated as of October 17, 2003, between IDEXX Europe B.V. (“IDEXX”) and Ortho-Clinical Diagnostics, Inc. (“OCD”).
ContractCertain • May 14th, 2003 • Intermune Inc • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Certain • April 5th, 2004 • Viacell Inc • Services-commercial physical & biological research • Massachusetts
RESTRUCTURED AND RESTATED HspE7 COLLABORATION AGREEMENT AMONG STRESSGEN DEVELOPMENT CORPORATION AND STRESSGEN BIOTECHNOLOGIES CORPORATION AND December 1, 2003Certain • February 19th, 2004 • Stressgen Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
This RESTRUCTURED AND RESTATED HSPE7 COLLABORATION AGREEMENT (“Agreement”) is made as of December 1, 2003 (the “Effective Date”) by and among, on the one hand, STRESSGEN DEVELOPMENT CORPORATION, a Barbados corporation, with its principal office at Whitepark House, White Park Road, P.O. Box 806E, Bridgetown, Barbados (“Stressgen”), and STRESSGEN BIOTECHNOLOGIES CORPORATION, a corporation organized under the laws of Yukon Territory, Canada, with its principal office at #350 – 4243 Glanford Avenue, Victoria, BC Canada V8Z 4B9 (“SBC”), and, on the other hand, F.HOFFMANN-LA ROCHE LTD, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070-Basel Switzerland and HOFFMANN-LA ROCHE INC., a New Jersey corporation, with its principal office at 340 Kingsland Street, Nutley, New Jersey 07110 (collectively, “Roche”).
AMENDMENT NO. 4 TO AGREEMENTCertain • February 16th, 2022 • Idexx Laboratories Inc /De • In vitro & in vivo diagnostic substances
AMENDMENT, effective as of December 28, 2011 (this “Amendment”) to the Agreement, dated as of October 16, 2003, between IDEXX Operations, Inc. (“IDEXX”) and Ortho-Clinical Diagnostics, Inc. (“OCD”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Certain • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
RE: Collaboration and License Agreement by and among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. effective October 16, 2017, as amended by letter agreement dated November 13, 2018, Amendment No. 1 to the Collaboration and License Agreement effective December 17, 2019, Amendment No. 2 to the Collaboration and License Agreement effective March 3, 2020 (“Amendment No. 2”) and Amendment No. 3 to the Collaboration and License Agreement effective April 1, 2020 (“Amendment No. 3”) (the “Collaboration Agreement”).
AMENDMENT #3 TO EXCLUSIVE LICENSE AGREEMENT # 2Certain • November 9th, 2016 • REVA Medical, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
WHEREAS Reva Medical Inc. (“REVA”) and Rutgers, The State University of New Jersey (“Rutgers”), referred to collectively herein as “the Parties”, entered into an EXCLUSIVE LICENSE AGREEMENT NUMBER 2 (“License #2) effective July 1, 2010; and,
Exhibit 10.11 [Logo Goes Here] BRIO SOFTWARE LICENSE AGREEMENT This Software License Agreement, ("Agreement") is made effective as of September 29, 1999 (the "Effective Date"), by and between Brio Technology Inc., a Delaware corporation with its...Certain • March 2nd, 2000 • Trinet Employer Group Inc
SECOND AMENDED AND RESTATED PRODUCTION AGREEMENT BETWEEN CARDINAL HEALTH 406, INC. AND MEDIMMUNE VACCINES, INC.Certain • March 9th, 2004 • Medimmune Inc /De • Biological products, (no disgnostic substances) • Pennsylvania
This Second Amended and Restated Production Agreement (the "Agreement") is made effective as of December 31, 2003 (the "Effective Date") by and between Cardinal Health 406, Inc., a Pennsylvania corporation with offices at 3001 Red Lion Road, Philadelphia, Pennsylvania 19114 (hereinafter called "Cardinal Health"); and MedImmune Vaccines, Inc., a Delaware corporation with offices at 35 West Watkins Mill Road, Gaithersburg, Maryland 20878 (hereinafter called "MedImmune"). Cardinal Health and MedImmune may be referred to herein as a "Party" or, collectively, as "Parties."
LICENSE AGREEMENTCertain • February 2nd, 2000 • Intermune Pharmaceuticals Inc • Wisconsin
EXCLUSIVE LICENSE AGREEMENTCertain • February 8th, 2012 • Q Holdings, Inc. • Pharmaceutical preparations • Utah
THIS EXCLUSIVE LICENSE AGREEMENT (“agreement”) is entered into this 5TH day of October, 2005 by and between the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah nonprofit corporation, having its principal place of business at 615 Arapeen Drive, Suite 310, Salt Lake City, UT 84108, hereinafter referred to as “LICENSOR,” and Q Therapeutics, Inc., a Delaware corporation having its principal place of business at 615 Arapeen Drive, Suite 102, Salt Lake City, UT 84108, hereinafter referred to as “LICENSEE.” This AGREEMENT replaces and consolidates a previous set of three license agreements entered into the 9th day of August, 2002 by and between LICENSOR and LICENSEE (then formerly known as Cue Therapeutics), identified by LICENSOR as Exclusive License #0837 for APCs, Exclusive License #0838 for GRPs, NCSCs and NEPs, and Non-Exclusive License #0840 for NEPs.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Certain • February 8th, 2021 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
This Project Agreement is awarded under the authority of MCDC Base Agreement No. 2020-504, and herein incorporates all the terms and conditions thereof, as such terms and conditions are modified by the terms of the Statement Of Work attached hereto as Exhibit A (the “Statement of Work” or “SOW”). The parties agree that, to the extent any terms or conditions of the Statement of Work conflict with the terms and conditions of MCDC Base Agreement No. 2020-504, the terms and conditions of the Statement of Work shall apply and take precedence.
AMENDMENT NUMBER FIVE TO WAFER SUPPLY AGREEMENTCertain • February 26th, 2010 • Power Integrations Inc • Semiconductors & related devices
This Amendment Number Five (the “Amendment”), effective as of December 1, 2009 (the “Amendment Effective Date”), amends the Wafer Supply Agreement effective as of May 23, 2003 (as previously amended) (the “Agreement”), by and between X-FAB Dresden GmbH & Co. KG (successor in interest to ZMD Analog Mixed Signal Services GmbH & CoKG) a German corporation (the “Company”) and Power Integrations International, Ltd. (“PI”) a Cayman Islands corporation having its principal place of business at 4th Floor, Century Yard, Cricket Square, Elgin Avenue, P.O. Box 32322, Grand Cayman KY 1-1209. Unless specifically designated otherwise, capitalized terms used herein shall have the same meanings given them in the Agreement.
FIRST AMENDMENT TO LICENSE AGREEMENT FOR [*]/SMALL MOLECULE, AND [*] PROTEIN TECHNOLOGIESCertain • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT FOR [*]/SMALL MOLECULE, AND [*] PROTEIN TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 22nd, 2003 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at Two Corporate Drive, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) having its statewide administrative offices at 1111 Franklin Street, 12 Floor, Oakland, California 94607-5200. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
Toll Manufacturing Agreement by and among Gilead World Markets, Ltd Queensgate House South Church Street PO Box 1234 GT Grand Cayman Cayman Islands Gilead Sciences, Inc. Foster City, CA 94404 USA and ALTANA Pharma Oranienburg GmbH Lehnitzstr. 70-98...Certain • March 11th, 2004 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This Amended And Restated Clinical and Commercial Supply Agreement (the “Agreement”) made and effective as of the 01 day of August, 2003 (the “Effective Date”) among, on the one hand, Gilead World Markets, Ltd., a Cayman Company (“Gilead World”), whose registered address is Queensgate House, South Church Street, P.O. Box 1234GT, Grand Cayman, Cayman Islands, and Gilead Sciences, Inc, a Delaware corporation (“Gilead Sciences”) with its principal office located at 333 Lakeside Drive, Foster City, CA 94404, USA (Gilead World and Gilead Sciences collectively, “GILEAD”), and, on the other hand, Altana Pharma Oranienburg GmbH, a German corporation (“APO”) having its principal place of business at Lehnitzstrasse 70-98, 16515 Oranienburg, Germany. Gilead and APO are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Certain • March 28th, 2024 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances)
COLLABORATION, OPTION, AND LICENSE AGREEMENTCertain • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATION, OPTION, AND LICENSE AGREEMENT (this “Agreement”) is made as of 23 May, 2018 (the “Execution Date), and effective as of the Effective Date (as defined herein) by and between VIR BIOTECHNOLOGY, INC., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, California 94158, United States of America (“Vir”), BIIG THERAPEUTICS LIMITED, DBA BRII BIOSCIENCES LIMITED, a corporation organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Parent”), and BRII BIOSCIENCES OFFSHORE LIMITED a corporation to be established by Parent in accordance with Section 17.1 of this Agreement and organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Brii Bi
ContractCertain • March 12th, 2020 • ViewRay, Inc. • Electromedical & electrotherapeutic apparatus
Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
ATAMESTANE LICENSE AGREEMENTCertain • November 3rd, 2000 • Biomedicines Inc
AMENDED AND RESTATED WORLDWIDE AGREEMENTCertain • March 16th, 2005 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances) • California
This Amended and Restated Worldwide Agreement is entered into as of October 1, 2003 (the “Effective Date”), by and among, on the one hand, HOFFMANN-LA ROCHE INC., a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche-Nutley”) and F. HOFFMANN-LA ROCHE LTD of Basel, Switzerland (“F. Roche”) (Roche-Nutley and F. Roche are hereinafter individually and collectively referred to as “Roche”) and, on the other hand, PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”).
RECITALSCertain • July 24th, 2001 • Omnicell Inc /Ca/ • Electronic computers • California
CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. ONEVISION® SERVICE AND...Certain • May 20th, 2008 • ForgeHouse, Inc. • Greeting cards
This Agreement is entered into effective as of the 25th day of April, 2007 (“Effective Date”), by and between ForgeHouse, LLC, a limited liability company organized and existing under the laws of the state of Georgia, US (hereinafter referred to as “FORGEHOUSE”), and Securitas Security Services USA, Inc., a corporation organized and existing under the laws of the state of Delaware, US (hereinafter referred to as "LICENSEE”).
FIRST AMENDMENT TO NATIONAL PRODUCT SUPPLY GOVERNANCE AGREEMENTCertain • February 27th, 2019 • Coca-Cola Consolidated, Inc. • Bottled & canned soft drinks & carbonated waters • Georgia
This First Amendment to National Product Supply Governance Agreement (this “Amendment”) is adopted and effective as of October 26, 2018 (the “Effective Date”) by The Coca‑Cola Company, a Delaware corporation acting by and through its Coca-Cola North America Division, and each of the other members of the Coca‑Cola National Product Supply Group (the “NPSG”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in that certain National Product Supply Governance Agreement (the “National Product Supply Governance Agreement”), by and among the members of the NPSG, including those party by joinder.
RECITALSCertain • August 4th, 2000 • Pharsight Corp • Services-prepackaged software • California
